PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07D 239/42, A61K 31/505, A61P 3/06 — A1

(11) International Publication Number: **WO 00/42024**

(43) International Publication Date: 20 July 2000 (20.07.00)

(21) International Application Number: PCT/GB99/04439

(22) International Filing Date: 23 December 1999 (23.12.99)

(30) Priority Data:
9900339.4 9 January 1999 (09.01.99) GB

(71) Applicant *(for all designated States except US)*: ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: TAYLOR, Nigel, Phillip [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: BRYANT, Tracey; Global Intellectual Property, Patents, AstraZeneca UK Limited, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: CRYSTALLINE BIS[(E)–7– [4–(4– FLUOROPHENYL)– 6–ISOPROPYL–2– [METHYL (METHYLSULFONYL) AMINO] PYRIMIDIN –5–YL] (3R,5S)–3, 5–DIHYDROXYHEPT –6–ENOIC ACID]CALCIUM SALT

(57) Abstract

The present invention relates to a crystalline form of the compound bis[(E)–7–[4–(4– fluorophenyl)– 6–isopropyl–2– [methyl (methylsulfonyl) amino] pyrimidin–5–yl] (3R, 5S)–3, 5–dihydroxyhept –6–enoic acid]calcium salt, as well as processes for its manufacture and pharmaceutical compositions comprising the crystalline form, which is useful as an agent for treating hyperlipidemia, hypercholesterolemia and atherosclerosis.